GleamWall
中文EN

BCTX BriaCell Therapeutics Corp.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1610820 · Fiscal year ends 07/31

Financial factors as of 2026-07-31 (2026Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-32.7%
TTM EPS YoY88.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-203.6%
ROA-154.3%
ROIC (approx.)-408.8%
Asset turnover—

Leverage & solvency

Liabilities / assets34.0%
Debt / equity0.00x
Current ratio2.76x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q4*2026-07-312026Q32026-04-302026Q22026-01-312026Q12025-10-312025Q4*2025-07-312025Q32025-04-302025Q22025-01-312025Q12024-10-31
Income statement
Revenue————————
R&D expense$10.53M$5.97M$6.05M$6.68M$7.11M$4.81M$5.68M$3.67M
SG&A expense$2.05M$1.65M$1.48M$1.64M$1.44M$1.52M$1.48M$1.49M
Operating income-$12.58M-$7.62M-$7.53M-$8.32M-$8.55M-$6.33M-$7.17M-$5.15M
Interest expense$0$29,631——$0$36,979——
Net income-$12.32M-$7.16M-$7.22M-$8.20M-$8.09M-$6.13M-$6.29M-$5.80M
EBITDA-$12.55M-$7.59M-$7.51M-$8.30M-$8.54M-$6.31M-$7.14M-$5.13M
EPS (basic)—-0.99-2.58-4.35—-16.42-23.31-32.67
EPS (diluted)—-0.99-2.58-4.35—-16.42-23.31-32.67
Weighted avg. shares (diluted)—7.25M2.80M1.88M—373,067269,957177,606
Balance sheet
Cash & equivalents$9.85M$6.88M$29.90M$2.71M$10.49M$12.46M$5.01M$5.79M
Short-term investments$10.69M$15.92M—$7.46M$7.37M———
Current assets$22.04M$25.39M$32.18M$11.35M$19.93M$14.79M$7.16M$8.22M
PP&E, net$319,804$348,997$251,141$273,980$296,819$319,658$342,497$365,336
Intangibles$169,254——$180,707$184,525$188,343$192,160$195,978
Total assets$23.58M$27.07M$33.59M$13.08M$21.65M$17.00M$9.36M$10.41M
Current liabilities$7.98M$3.59M$3.19M$3.32M$3.98M$4.33M$5.23M$4.99M
Total liabilities$8.02M$3.66M$3.38M$3.72M$4.32M$5.06M$6.14M$6.70M
Shareholders' equity$16.40M$24.06M$30.92M$9.98M$17.88M$12.42M$3.60M$4.04M
Shares outstanding8.71M7.25M7.25M—1.88M6.56M294,69436.18M
Cash flow statement
Operating cash flow-$5.96M-$7.02M-$7.97M-$7.70M-$8.13M-$7.16M-$5.92M-$6.96M
Capital expenditure$0———————
Free cash flow-$5.96M———————
Investing cash flow$4.99M-$16.00M$7.28M-$75,000-$7.39M-$105,000-$75,000-$75,000
Financing cash flow$3.94M$0——$13.56M$14.71M$5.22M$11.96M
Depreciation & amortization$29,193$29,193$22,839$22,839$11,386$22,839$30,475$22,839
Stock-based compensation$117,529$432,207$285,856$294,686$0$224,815$285,093$266,971

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.